Halah Dawood Salman (1)
General Background: Bacterial resistance to antibiotics continues to intensify worldwide, creating an urgent need for adjunct therapies that enhance antimicrobial efficacy. Specific Background: Metformin, a widely used antidiabetic drug, has shown immunomodulatory and antimicrobial properties, yet its effects on vaginal pathogens in women with and without polycystic ovary syndrome (PCOS) remain insufficiently explored. Knowledge Gap: Limited evidence exists regarding whether metformin can potentiate antibiotic activity against common vaginal bacterial isolates, particularly in PCOS patients who often exhibit reduced IL-10 levels and heightened inflammatory states. Aims: This study aimed to evaluate the adjuvant antibacterial effect of metformin when combined with standard antibiotics against Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa isolated from affected women. Results: Metformin enhanced antibiotic inhibition zones notably for K. pneumoniae and P. aeruginosa, while producing a moderate but less consistent synergistic effect on E. coli. Serum IL-10 levels were significantly lower in patients than controls, confirming an underlying inflammatory imbalance. Novelty: This research provides one of the first empirical assessments of metformin’s antibacterial adjuvant role in vaginal infections among PCOS and non-PCOS women. Implications: Findings suggest metformin may serve as a promising supportive agent to strengthen antibiotic efficacy and help mitigate bacterial resistance.Highlight :
Keywords : Metformin, Vaginal Infection, PCOS, Antibacterial Synergy, Antibiotic Resistance
World Health Organization, “Polycystic Ovary Syndrome,” 2023, Available: [https://www.who.int/](https://www.who.int/)
A. M. Elsayed et al., “Clinical Phenotypes of PCOS: A Cross-Sectional Study,” Reproductive Sciences, vol. 1, pp. 1–12, 2023.
D. Fang and J. Zhu, “Molecular Switches for Regulating the Differentiation of Inflammatory and IL-10-Producing Anti-Inflammatory T-Helper Cells,” Cellular and Molecular Life Sciences, vol. 77, pp. 289–303, 2020, doi: 10.1007/s00018-019-03282-4.
J. Liu, Q. Liu, and X. Chen, “The Immunomodulatory Effects of Mesenchymal Stem Cells on Regulatory B Cells,” Frontiers in Immunology, vol. 11, 551680, 2020, doi: 10.3389/fimmu.2020.551680.
C. M. Farquhar et al., “The Prevalence of Polycystic Ovaries on Ultrasound Scanning in a Population of Randomly Selected Women,” Australian and New Zealand Journal of Obstetrics and Gynaecology, vol. 34, pp. 67–72, 1994.
M. Rostamtabar et al., “Pathophysiological Roles of Chronic Low-Grade Inflammation Mediators in Polycystic Ovary Syndrome,” Journal of Cellular Physiology, vol. 236, pp. 824–838, 2021.
T. Artimani et al., “Evaluation of Pro-Oxidant–Antioxidant Balance and Its Association With Inflammatory Cytokines in Polycystic Ovary Syndrome,” Gynecological Endocrinology, vol. 34, pp. 148–152, 2018.
L. S. Hermann et al., “Therapeutic Comparison of Metformin and Sulfonylurea, Alone and in Various Combinations: A Double-Blind Controlled Study,” Diabetes Care, vol. 17, pp. 1100–1109, 1994.
UKPDS Group, “Effect of Intensive Blood Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes,” Lancet, vol. 352, pp. 854–865, 1998.
R. A. DeFronzo and A. M. Goodman, “Efficacy of Metformin in Patients With Non-Insulin-Dependent Diabetes Mellitus,” New England Journal of Medicine, vol. 333, pp. 541–549, 1995.
K. Johansen, “Efficacy of Metformin in the Treatment of NIDDM: Meta-Analysis,” Diabetes Care, vol. 22, pp. 33–37, 1999.
A. J. Garber et al., “Efficacy of Metformin in Type II Diabetes: Results of a Double-Blind, Placebo-Controlled, Dose-Response Trial,” American Journal of Medicine, vol. 103, pp. 491–497, 1997.
M. B. Davidson and A. L. Peters, “An Overview of Metformin in the Treatment of Type 2 Diabetes Mellitus,” American Journal of Medicine, vol. 102, pp. 99–110, 1997.
C. J. Bailey and R. C. Turner, “Metformin,” New England Journal of Medicine, vol. 334, pp. 574–579, 1996.
K. Cusi and R. A. DeFronzo, “Metformin: A Review of Its Metabolic Effects,” Diabetes Reviews, vol. 6, pp. 89–131, 1998.
H. Yki-Jarvinen, K. Nikkila, and S. Makimattila, “Metformin Prevents Weight Gain and Improves Metabolic Parameters in Abdominally Obese Women With and Without Polycystic Ovary Syndrome,” Journal of Clinical Endocrinology and Metabolism, 1999.
L. J. Dominguez et al., “Effects of Metformin on Tyrosine Kinase Activity, Glucose Transport, and Intracellular Calcium in Rat Vascular Smooth Muscle,” Endocrinology, vol. 137, pp. 113–121, 1996.
D. Argaud et al., “Metformin Decreases Gluconeogenesis by Enhancing the Pyruvate Kinase Flux in Isolated Rat Hepatocytes,” European Journal of Biochemistry, vol. 213, pp. 1341–1348, 1993.
A. Dresner et al., “Effects of Free Fatty Acids on Glucose Transport and IRS-1-Associated PI3-Kinase Activity,” Journal of Clinical Investigation, vol. 103, pp. 253–259, 1999.
G. Patane et al., “Metformin Restores Insulin Secretion Altered by Chronic Exposure to Free Fatty Acids,” Diabetes, vol. 49, pp. 735–740, 2000.
C. Wilcock and C. J. Bailey, “Reconsideration of Inhibitory Effect of Metformin on Intestinal Glucose Absorption,” Journal of Pharmacy and Pharmacology, vol. 43, pp. 120–121, 1991.
J. E. Nestler, “Metformin for the Treatment of the Polycystic Ovary Syndrome,” New England Journal of Medicine, vol. 358, pp. 47–54, 2008.
M. Pollak, “The Effects of Metformin on Gut Microbiota and the Immune System,” Diabetologia, vol. 60, pp. 1662–1667, 2017.
E. Thursby and N. Juge, “Introduction to the Human Gut Microbiota,” Biochemical Journal, vol. 474, pp. 1823–1836, 2017.
D. Stepensky et al., “Pharmacokinetic–Pharmacodynamic Analysis of Metformin in Diabetic Rats,” Drug Metabolism and Disposition, vol. 30, no. 8, pp. 861–868, 2002.
G. G. Graham et al., “Clinical Pharmacokinetics of Metformin,” Clinical Pharmacokinetics, vol. 50, no. 2, pp. 81–98, 2011.
B. D. Novita et al., “Metformin-Induced Autophagy in Diabetes–Tuberculosis Co-Infection: A Case Study,” Indian Journal of Tuberculosis, vol. 66, no. 1, pp. 64–69, 2019.
Y. Liu et al., “Metformin Restores Tetracycline Susceptibility Against Multidrug-Resistant Bacteria,” Advanced Science, vol. 7, no. 12, 1902227, 2020, doi: 10.1002/advs.201902227.
C. T. Bramante et al., “Metformin and Risk of Mortality in Hospitalized COVID-19 Patients,” Lancet Healthy Longevity, vol. 2, pp. e34–e41, 2021.
K. Maniar et al., “Metformin–Butyrate Synergism and Gut Microbiome Modification,” Pharmacological Research, vol. 117, pp. 103–128, 2017.
W. A. H. Hegazy et al., “Repurposing Anti-Diabetic Drugs to Cripple Quorum Sensing in Pseudomonas Aeruginosa,” Microorganisms, vol. 8, p. 1, 2020.
J. L. Tarry-Adkins, C. E. Aiken, and S. E. Ozanne, “Neonatal, Infant, and Childhood Growth After Metformin vs Insulin for Gestational Diabetes,” PLoS Medicine, vol. 16, pp. 1–20, 2019.
W. A. H. Hegazy et al., “Repurposing Anti-Diabetic Drugs to Cripple Quorum Sensing in Pseudomonas Aeruginosa,” Microorganisms, vol. 8, 1285, 2020.
W. A. H. Hegazy et al., “Repurposing Antidiabetics as Serratia Marcescens Virulence Inhibitors,” Brazilian Journal of Microbiology, vol. 52, pp. 627–638, 2021.
M. M. Masadeh et al., “Metformin as a Potential Adjuvant Antimicrobial Agent,” Clinical Pharmacology, vol. 13, pp. 83–90, 2021.
S. A. Gnanadass, Y. D. Prabhu, and A. V. Gopalakrishnan, “Association of Metabolic and Inflammatory Markers With PCOS,” Archives of Gynecology and Obstetrics, vol. 303, pp. 631–643, 2021.
R. M. Chugh et al., “Mesenchymal Stem Cell Therapy Restores Fertility in a PCOS Mouse Model via IL-10,” Stem Cell Research and Therapy, vol. 12, pp. 1–19, 2021.
M. Umar, K. S. Sastry, and A. I. Chouchane, “Role of Vitamin D Beyond Skeletal Function,” International Journal of Molecular Sciences, vol. 19, 1618, 2018.
Lakshmi et al., “Bacterial Vaginal Infections in Diabetic and Non-Diabetic Women,” BMC Infectious Diseases, vol. 12, suppl. 1, P63, 2012.
T. R. P., S. Patil, S. Patil, and A. Patil, “Antimicrobial Potential of Metformin,” International Journal of Pharmacognosy and Phytochemical Research, vol. 11, no. 3, pp. 230–234, 2019.
A. Mor et al., “Metformin and Glucose-Lowering Drugs and Infection Rates,” BMJ Open, vol. 6, e011523, 2016.
Y. Xiao et al., “Metformin Promotes Innate Immunity Through a PMK-1/p38 MAPK Pathway,” Virulence, vol. 11, no. 1, pp. 39–48, 2020.
Y. Liu et al., “Metformin Restores Tetracycline Susceptibility Against Multidrug-Resistant Bacteria,” Advanced Science, 1902227, 2020.
F. Nasrin, “Antimicrobial and Antioxidant Potential of Metformin,” International Journal of Pharmaceutical and Drug Analysis, pp. 220–224, 2014.
S. K. Gi et al., “Increased Airway Glucose Increases Airway Bacterial Load in Hyperglycemia,” Scientific Reports, vol. 6, p. 1, 2016.